



SDS: COSOPT® PF (dorzolamide hydrochloride-timolol maleate ophthalmic solution) 2%/0.5%

SAFETY DATA SHEET

1. Identification

Product Identifier: COSOPT® PF (dorzolamide hydrochloride-timolol maleate ophthalmic solution) 2%/0.5%

Synonyms: Dorzolamide Hydrochloride - Timolol Maleate Ophthalmic Solution; (4S-trans)-4-(ethylamino)-5,6-dihydro-6-methyl-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide monohydrochloride and (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt)

National Drug Code (NDC): 17478-604-30
17478-604-90

Recommended Use: Pharmaceutical.

Company: Akorn, Inc.
1925 West Field Court, Suite 300
Lake Forest, Illinois 60045

Contact Telephone: 1-800-932-5676

E mail: customer.service@akorn.com

Emergency Phone Number: CHEMTREC 1-800-424-9300 (U.S. and Canada)

2. Hazard(s) Identification

Physical Hazards: Not classifiable.
Health Hazards: Not classifiable.
Symbol(s): None.
Signal Word: None.
Hazard Statement(s): None.
Precautionary Statement(s): None.
Hazards Not Otherwise Classified: Not classifiable.

Supplementary Information: While this material is not classifiable as hazardous under the OSHA standard, this SDS contains valuable information critical to safe handling and proper use of the product. This SDS should be retained and available for employees and other users of this product.

**SDS: COSOPT® PF (dorzolamide hydrochloride-
timolol maleate ophthalmic solution) 2%/0.5%**

3. Composition/Information on Ingredients

Chemical Name	CAS Number	Synonyms	Chemical Formula	Molecular Weight	Percentage
(4S-trans)-4-(ethylamino)-5,6-dihydro-6-methyl-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide monohydrochloride	130693-82-2	Dorzolamide hydrochloride; Dorzolamide HCl	C ₁₀ H ₁₆ N ₂ O ₄ S ₃ •HCl	360.91	2.266% (2% as base)
(-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt)	26921-17-5	Timolol maleate	C ₁₃ H ₂₄ N ₄ O ₃ S•C ₄ H ₄ O ₄	432.50	0.683% (0.5% as base)

*(The formulation for this product is proprietary information. Only hazardous ingredients in concentrations of 1% or greater and/or carcinogenic ingredients in concentrations of 0.1% or greater are listed in the composition table. Active ingredients in any concentration are listed).

4. First Aid Measures

Ingestion:

If a person vomits place them in the recovery position so that vomit will not reenter the mouth and throat. Rinse mouth with water. If swallowed, seek medical advice immediately and show the container or label. Treat symptomatically and supportively. Ensure that medical personnel are aware of the material(s) involved and take precautions to protect themselves.

Eye Contact:

Remove from source of exposure. Flush with copious amounts of water for at least 15 minutes. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary. Ensure that medical personnel are aware of the material(s) involved and are aware of precautions to protect themselves.

Skin Contact:

Remove from source of exposure. Remove and isolate contaminated clothing and shoes. Flush with copious amounts of water for at least 20 minutes. Use soap. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary. Ensure that medical personnel are aware of the material(s) involved and are aware of precautions to protect themselves.

Inhalation:

Remove from source of exposure. Move individual(s) to fresh air. Give artificial respiration if individual(s) are not breathing and call emergency medical service. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary. Ensure that medical personnel are aware of the material(s) involved and are aware of precautions to protect themselves.

Protection of First-Aiders:

Use personal protective equipment (see section 8).

SDS: COSOPT® PF (dorzolamide hydrochloride-timolol maleate ophthalmic solution) 2%/0.5%

Signs and Symptoms: Ocular burning and/or stinging; eye redness and itching; blurred vision and keratitis; dyspnea, respiratory failure, contact dermatitis, bradycardia, heart block, choroidal detachment following infiltration surgery and nausea.

Medical Conditions Aggravated by Exposure: Chronic respiratory and obstructive airway diseases, kidney problems, cardiac disease allergic reactions.

Notes to Physician: This product contains a sulfonamide (Dorzolamide hydrochloride) and a beta-adrenergic blocking agent (Timolol maleate), which are absorbed systemically. Symptoms consistent with systemic administration of beta-blockers or carbonic anhydrase inhibitors may occur, including electrolyte imbalance, development of an acidotic state, dizziness, headache, shortness of breath, bradycardia, bronchospasm, cardiac arrest and possible central nervous system effects. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored. Treat supportively and symptomatically.

5. Firefighting Measures

Suitable Extinguishing Media: Use extinguishing media for type of surrounding fire.

Unsuitable Extinguishing Media: Not determined.

Specific Hazards Arising from the Chemical:

Hazardous Combustion Products: These products include carbon oxides, nitrogen oxides, sulfur oxides, and hydrogen chloride.

Other Specific Hazards: Closed containers may explode from the heat of fire.

Special Protective Equipment/Precautions for Firefighters: Wear self-contained breathing apparatus and full and protective gear.

6. Accidental Release Measures

Personal Precautions: Keep unnecessary personnel away. Do not touch damaged containers or spilled material unless wearing appropriate personal protective equipment and clothing.

Personal Protective Equipment: For personal protection see section 8.

Methods for Cleaning Up: Dike ahead of liquid spills for later disposal. Absorb with inert material. Recover product and place in an appropriate container for disposal in accordance with local, state and federal regulations.

Environmental Precautions: Contain material and prevent release to basements, confined spaces, waterways or soil.

Reference to Other Sections: Refer to Sections 8, 12 and 13 for further information.

SDS: COSOPT® PF (dorzolamide hydrochloride-timolol maleate ophthalmic solution) 2%/0.5%

7. Handling and Storage

Precautions for Safe Handling: Handle in accordance with product label and/or product insert information. Handle in accordance with good industrial hygiene and safety practices.

Conditions for Safe Storage, Including Any Incompatibilities: Store according to label and/or product insert information. Store away from oxidizers, acids, and bases.

Specific End Use: Pharmaceuticals.

8. Exposure Controls/Personal Protection

Occupational Exposure Guidelines:

Common or Chemical Name	Employee Exposure Limits
Dorzolamide Hydrochloride	OEL*: 0.04 mg/m ³ , 8 Hour TWA
Timolol Maleate	OEL*: 0.015 mg/m ³ , 8 Hour TWA**

* Occupational Exposure Levels (OELs) have been established by private industry.

** An eye notation has been assigned to this compound because absorption through the eyes may contribute significantly to the overall exposure and produce systemic effects.

Engineering Controls: Engineering controls should be used as the primary means to control exposures.

Respiratory Protection: Where respirators are deemed necessary to reduce or control occupational exposures, use NIOSH-approved respiratory protection and have an effective respirator program in place (applicable U.S. regulation OSHA 29 CFR 1910.134).

Eyes Protection: Safety glasses with side shields are recommended. Face shields or goggles may be required if splash potential exists or if corrosive materials are present. Approved eye protection (e.g., bearing the ANSI Z87 or CSA stamp) is preferred. Maintain eyewash facilities in the work area.

Hand Protection: Chemically compatible gloves. For handling solutions, ensure that the glove material is protective against the solvent being used. Use handling practices that minimize direct hand contact. Employees who are sensitive to natural rubber (latex) should use nitrile or other synthetic non-latex gloves. Use of powdered latex gloves should be avoided due to the risk of latex allergy.

Skin Protection: Protective laboratory coat, apron, or disposable garment.

**SDS: COSOPT® PF (dorzolamide hydrochloride-
timolol maleate ophthalmic solution) 2%/0.5%**

9. Physical and Chemical Properties

Physical State/Color:	Liquid/Colorless.
Odor:	No data available.
Odor Threshold:	No data available.
pH:	No data available.
Melting Point:	No data available.
Freezing Point:	No data available.
Boiling Point:	No data available.
Flash Point:	No data available.
Evaporation Rate:	No data available.
Flammability (solid, gas):	No data available.
Flammability Limit - Lower:	No data available.
Flammability Limit - Upper:	No data available.
Vapor Pressure:	No data available.
Vapor Density:	No data available.
Relative Density:	No data available.
Solubility(ies):	Miscible in water.
Partition Coefficient (n-octanol/water):	No data available.
Auto-Ignition Temperature:	No data available.
Decomposition Temperature:	No data available.
Viscosity:	No data available.

10. Stability and Reactivity

Reactivity:	No data available.
Chemical Stability:	Stable under recommended storage conditions.
Possibility of Hazardous Reactions:	No data available.
Conditions to Avoid (e.g., static discharge, shock, or vibration):	No data available.
Incompatible Materials:	Oxidizers, acids, bases.
Hazardous Decomposition Products:	No data available.

11. Toxicological Information

Information on the Likely Routes of Exposure:

Inhalation:	May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion:	May be harmful if swallowed.
Skin Contact:	May be harmful if absorbed through the skin. May cause irritation.
Eye Contact:	May cause eye irritation.

SDS: COSOPT® PF (dorzolamide hydrochloride-timolol maleate ophthalmic solution) 2%/0.5%

Symptoms Related to the Physical, Chemical and Toxicological Characteristics:

See Section 4. To the best of our knowledge, the chemical, physical and toxicological properties have not been thoroughly investigated.

Delayed and Immediate Effects of Exposure:

No data available.

Acute Toxicity:

Compound	Species	Route	Test Type	Dose
Dorzolamide Hydrochloride	Rat	Oral	LD ₅₀	1,927 mg/kg
Timolol Maleate	Rat	Oral	LD ₅₀	>900 – 1,800 mg/kg

Acute Toxicity – Dermal: No data available.
Acute Toxicity – Inhalation: No data available.
Corrosivity: No data available.
Dermal Irritation: No data available.
Eye Irritation: No data available.
Sensitization: No data available.
Toxicokinetics/Metabolism: No data available.
Target Organ Effects: No data available.
Reproductive Effects: No data available.
Carcinogenicity: No data available.

National Toxicology Program (NTP): Not considered to be a carcinogen.

International Agency for Research on Cancer (IARC): Not considered to be a carcinogen.

Occupational Safety and Health Administration (OSHA): Not considered to be a carcinogen.

Mutagenicity: No data available.
Aspiration Hazard: No data available.

12. Ecological Information

Ecotoxicity

Aquatic:

Compound	Species	Test Type	Dose
Dorzolamide Hydrochloride	Daphnia magna	EC ₅₀	699 mg/l (48 Hours)
Timolol Maleate	Daphnia magna	EC ₅₀	161 mg/l (48 Hours)

Terrestrial: No data available.
Persistence and Degradability: No data available.
Bioaccumulative Potential: No data available.
Mobility in Soil: No data available.
Mobility in Environment: No data available.
Other Adverse Effects: No data available.



SDS: COSOPT® PF (dorzolamide hydrochloride-timolol maleate ophthalmic solution) 2%/0.5%

13. Disposal Considerations

Dispose of all waste in accordance with Federal, State and Local regulations.

14. Transport Information

UN Number: Not applicable.
UN Proper Shipping Name: Not applicable.
Transport Hazard Class(es): Not applicable.
Packing Group: Not applicable.

Department of Transportation: Not regulated as a hazardous material.

International Air Transport Association (IATA): Not regulated as a dangerous good.

International Maritime Dangerous Good (IMDG): Not regulated as a dangerous good.

15. Regulatory Information

US Federal Regulations:

Toxic Substance Control Act (TSCA): This product is a drug regulated by the Food and Drug Administration (FDA), and is not regulated by TSCA.

CERCLA Hazardous Substance and Reportable Quantity: Not listed.

SARA 313: Not listed.
SARA 302: Not listed.

State Regulations

Massachusetts: Not listed.
New Jersey: Timolol Maleate.
Pennsylvania: Timolol Maleate.
California Proposition 65: Not listed.

16. Other Information

NFPA Rating:
Health: 1
Flammability: 0
Reactivity: 0

Revision Date: 06/23/2015

Revision Number: 1

Disclaimer: This document is generated to distribute health, safety and environmental data. It is not a specification sheet and none of the displayed data should be construed as a specification. Information on this SDS sheet was obtained from sources which we believe are reliable, and we believe that the information is complete and accurate. However, the information is provided without any warranty, express or implied, regarding its correctness. Some of the information presented and conclusions drawn are from sources other than direct test data of the substance. The conditions or methods of handling, storage, use and disposal of the product are beyond our control and may also be beyond our knowledge. It is the user's responsibility to determine the suitability of any material for a specific purpose and to adopt such safety precautions as may be necessary. If the product is used as a component in another product, this SDS information may not be applicable. For these reasons, we do not assume any responsibility and expressly disclaim liability for any loss, damage or expense arising out of or in any way connected with the handling, storage, use or disposal of this product.